Roche Makes a $5.7 Billion Hostile Bid for Illumina (ILMN)

This week, Swiss pharmaceutical giant Roche launched a hostile bid for San Diego-based Illumina (ILMN: Charts, News, Offers), the market leader in gene sequencing technology, for $5.7 billion, or $44.50 per share. Roche has given Illumina ten days t…
This article was written by InvestorGuide.com.